Award Number: DAMD17-01-1-0589

TITLE: The Effect of COX-2 Inhibitors on the Aromatase Gene Expression in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Charles L. Shapiro, M.D.
William Burak, M.D.
Robert Brueggemeier, Ph.D.

CONTRACTING ORGANIZATION: Ohio State University Medical Center Columbus, Ohio 43210

REPORT DATE: June 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031126 010
The Effect of COX-2 Inhibitors on the Aromatase Gene Expression in Human Breast Cancer

Charles L. Shapiro, M.D.
William Burak, M.D.
Robert Brueggemeier, Ph.D.

Ohio State University Medical Center
Columbus, Ohio 43210

E-Mail: Shapiro-l@medctr.osu.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited
Table of Contents

Cover.................................................................................. 1
SF 298 .................................................................................. 2
Table of Contents................................................................. 3
Introduction........................................................................... 4
Body...................................................................................... 4
Key Research Accomplishments.......................................... 4
Reportable Outcomes.......................................................... 4
Conclusions.......................................................................... 4
References............................................................................ 4
Appendices.......................................................................... 4
INTRODUCTION

This study will test the hypothesis that celecoxib, a selective Cox-2 inhibitor, will decrease PG, decrease the expression of CYP19, and reduce estrogen biosynthesis within tumor tissue. The primary objective of the study is to evaluate Aromatase (CYP19) and estrogen receptor (ER) gene expression by reverse-transcriptase polymerase chain reaction (RT-PCR) in response to a selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, in paired tumor tissue collected at the time of the initial diagnosis and at the time of definitive surgery for localized, non-metastatic breast cancer patients. The secondary objective is to evaluate the effect of celecoxib on the following biomarkers: estrogen receptor, progesterone receptor, Her-2/neu, Ki-67, COX-1, COX-2, CYP19, CD31, and PGE2, and Aromatase activity in paired tissue specimens by standard immunohistochemical methods. The study has been approved by both The Ohio State University IRB and the Army. In total, 34 subjects will be enrolled on the study. We anticipate that all 34 patients will be enrolled by May 31, 2004. The Army approved an extension to the performance period in March 2003. The performance period is now June 1, 2001 - June 30, 2004 (research to be completed by May 31, 2004).

BODY

Study staff began to screen for potential subjects in May 2003. As of May 31, 2003, no subjects were enrolled on the study.

KEY RESEARCH ACCOMPLISHMENTS

Not applicable. No patients have been enrolled on the study.

REPORTABLE OUTCOMES

Not applicable. No patients have been enrolled on the study.

CONCLUSIONS

Not applicable. No patients have been enrolled on the study.

REFERENCES

Not applicable. No patients have been enrolled on the study.

APPENDICES

Not applicable. No patients have been enrolled on the study.